for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Odonate Therapeutics Inc

ODT.OQ

Latest Trade

3.00USD

Change

-0.21(-6.54%)

Volume

276,345

Today's Range

3.00

 - 

3.28

52 Week Range

2.81

 - 

28.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.21
Open
3.20
Volume
276,345
3M AVG Volume
13.86
Today's High
3.28
Today's Low
3.00
52 Week High
28.25
52 Week Low
2.81
Shares Out (MIL)
38.50
Market Cap (MIL)
115.50
Forward P/E
-1.74
Dividend (Yield %)
--

Next Event

Q3 2021 Odonate Therapeutics Inc Earnings Release

Latest Developments

更多

Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58

Odonate Therapeutics - Qtrly Loss Per Share Of $0.90

Odonate Therapeutics Announces Financial Results For The Three And Twelve Months Ended December 31, 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Odonate Therapeutics Inc

Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). The Company's tesetaxel can be administered orally with a low pill burden and dosing regimen. Taxanes destroy cancer cells by preventing them from entering mitosis and thereby leading to apoptosis (cell death).

Industry

Biotechnology & Drugs

Contact Info

3 East 28Th Street, 10Th Floor

NEW YORK, NY

10016

United States

+1.858.2003830

https://www.odonate.com/

Executive Leadership

Kevin C Tang

Chairman of the Board, Chief Executive Officer

Michael S. Hearne

Chief Financial Officer

Robert Harvey Rosen

Director

Aaron I. Davis

Independent Director

Laura Johnson Douglass

Independent Director

Key Stats

3.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-3.640

2019

-4.050

2020

-3.840

2021(E)

-1.729
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.36
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-120.91
Return on Equity (TTM)
-94.35

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up